Holzgreve Adrien, Hellwig Dirk, Barthel Henryk, Beer Ambros J, Kobe Carsten, Lapa Constantin, Miederer Matthias, Schwarzenböck Sarah, Seifert Robert, Todica Andrei, Herrmann Ken, Bengel Frank M, Schäfers Michael, Moka Detlef, Luster Markus, Fendler Wolfgang P
PET Committee of the German Society of Nuclear Medicine, Göttingen, Germany.
Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Eur J Nucl Med Mol Imaging. 2025 May 3. doi: 10.1007/s00259-025-07323-x.
PET imaging is a key diagnostic procedure in clinical routine worldwide. While public figures on PET volume are available in many countries, until now these numbers were not publicly known for Germany.
On behalf of the PET committee of the German Society of Nuclear Medicine, we conducted a comprehensive survey among PET centers in Germany to collect data on PET imaging, including the total PET volume and indication groups.
National total PET volume in 2021 was 154,400 scans (94% PET/CT, 6% PET/MRI). PET volume in 2021 normalized to total population was lower in Germany (1,857 scans per 1 million inhabitants) when compared to public figures from France (10,182 scans), Belgium (9,866 scans), or Italy (4,312 scans). PET volume in Germany demonstrated significant growth 2017 to 2021 (+ 48%). Top three indication fields were oncological (re)staging (76%), theranostic (13%), and neurology (4%). The top three indications were lung cancer (31%), prostate cancer (16%), and lymphoma/leukemia (12%). The top three radiotracers used were [F]FDG (75%), PSMA radioligands (17%), and somatostatin-receptor radioligands (8%).
Clinical adoption of PET imaging in Germany is behind compared to Italy, France, and Belgium. However, newly established outpatient reimbursement seems to contribute to recent growth in PET volume. We observe considerable shift towards theranostic applications.
PET成像在全球临床常规诊断中是一项关键程序。虽然许多国家都有PET检查量的公开数据，但到目前为止，德国的这些数据尚未公开。
我们代表德国核医学协会的PET委员会，对德国的PET中心进行了全面调查，以收集PET成像的数据，包括PET检查总量和适应症组。
2021年全国PET检查总量为154,400次扫描（94%为PET/CT，6%为PET/MRI）。与法国（每百万居民10,182次扫描）、比利时（9,866次扫描）或意大利（4,312次扫描）的公开数据相比，2021年德国按总人口归一化后的PET检查量较低（每百万居民1,857次扫描）。德国的PET检查量在2017年至2021年期间显著增长（+48%）。前三大适应症领域是肿瘤（再）分期（76%）、诊疗一体化（13%）和神经科（4%）。前三大适应症是肺癌（31%）、前列腺癌（16%）和淋巴瘤/白血病（12%）。使用的前三大放射性示踪剂是[F]FDG（75%）、PSMA放射性配体（17%）和生长抑素受体放射性配体（8%）。
与意大利、法国和比利时相比，德国PET成像的临床应用相对滞后。然而，新设立的门诊报销似乎推动了近期PET检查量的增长。我们观察到向诊疗一体化应用的显著转变。
